Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORTHO-NOVUM 7/7/7-21 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy in women who elect to use an oral contraceptive
Prevention of pregnancy
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Metabolized primarily by CYP3A4; norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes hydroxylation and glucuronidation.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Ethinyl estradiol: 95-98% bound to albumin and SHBG; norethindrone: 60-70% bound to SHBG and albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: 2.5-4 L/kg; norethindrone: 3.5-5 L/kg; indicates extensive tissue distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: ~40-50% for ethinyl estradiol (first-pass metabolism); ~60-70% for norethindrone.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment (GFR 30-89 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min) due to potential fluid retention and electrolyte disturbances.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; no specific dose adjustment, but monitor for signs of hepatic toxicity.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use before menarche. Post-menarche adolescents: same dosing as adults. Weight-based adjustments not established; use standard adult regimen.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for postmenopausal women. Use in perimenopausal women: standard dosing with consideration of increased thrombotic risk and comorbidities.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thrombotic disorders (e.g., venous thromboembolism, stroke, myocardial infarction),Hepatic disease (e.g., jaundice, liver tumors),Hypertension,Carbohydrate and lipid metabolism effects,Headache/migraine,Bleeding irregularities,Depression,Gallbladder disease,Hereditary angioedema,Pregnancy and postpartum use,Ophthalmic complaints (contact lens intolerance, retinal thrombosis)
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
High risk of arterial or venous thrombotic diseases (e.g., known thrombophilia, history of DVT/PE, cerebrovascular disease, coronary artery disease),Current or history of breast cancer or other estrogen-sensitive cancer,Hepatic adenoma or carcinoma, or active liver disease,Undiagnosed abnormal uterine bleeding,Pregnancy,Hypersensitivity to any component,Smoking and age >35 years,Hypertension uncontrolled or with vascular disease,Migraine with aura if >35 years,Diabetes with nephropathy, retinopathy, neuropathy, or other vascular disease
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may increase estrogen exposure; avoid large amounts. Taking with food can reduce nausea.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Combined hormonal contraceptives like ORTHO-NOVUM 7/7/7-21 are contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on current data, but there is a small increased risk of cardiovascular and limb defects. Second and third trimester exposure has been associated with fetal harm including masculinization of female genitalia (due to progestin) and potential long-term effects. Use during pregnancy is not indicated; if pregnancy occurs, discontinue immediately.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Combined hormonal contraceptives may reduce milk production and quality, especially in early postpartum. Small amounts of estrogen and progestin are excreted in breast milk; the M/P ratio is not well defined for this specific formulation. Use is generally not recommended during breastfeeding, particularly before weaning or beyond 6 weeks postpartum when milk supply is established. Alternatives (progestin-only) are preferred.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Not applicable; this drug is contraindicated during pregnancy. No dose adjustments are made for pregnancy as it is not used in that setting. Pharmacokinetic changes of pregnancy (e.g., increased clearance) are not relevant because use is avoided.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
This triphasic oral contraceptive contains norethindrone and ethinyl estradiol. The 7/7/7-21 regimen uses three different hormone doses over 21 days followed by 7 placebo pills. Monitor for breakthrough bleeding, especially during dose transitions. Assess for contraindications including history of DVT, PE, migraine with aura, breast cancer, liver disease, or age >35 with smoking. Consider CYP3A4 interactions; rifampin, certain anticonvulsants, and St. John's wort may reduce efficacy.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time; missing pills increases pregnancy risk.,Start pack on first day of period or first Sunday after; use backup contraception for first 7 days if starting later.,Common side effects: nausea, breast tenderness, breakthrough bleeding; usually improve within 3 cycles.,Do not smoke while taking this medication; smoking increases risk of serious cardiovascular side effects.,Seek emergency care if signs of blood clot: sudden leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes.,Some medications (antibiotics, seizure meds, St. John's wort) may decrease effectiveness; inform all healthcare providers.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORTHO-NOVUM 7/7/7-21 vs ALYACEN 7/7/7, answered by our medical review team.
ORTHO-NOVUM 7/7/7-21 is a Oral Contraceptive that works by Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORTHO-NOVUM 7/7/7-21 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORTHO-NOVUM 7/7/7-21 is: One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORTHO-NOVUM 7/7/7-21 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORTHO-NOVUM 7/7/7-21 is classified as Category C. Combined hormonal contraceptives like ORTHO-NOVUM 7/7/7-21 are contraindicated in pregnancy. First trimester exposure is not associated with major malformations based on current da. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.